# A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

> **NCT05643508** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 214 (actual)

## Conditions studied

- Hypertension
- Hyperlipidemias

## Interventions

- **DRUG:** (D) DWC202206
- **DRUG:** (D) DWC202207
- **DRUG:** (P) DWC202206
- **DRUG:** (P) DWC202207

## Key facts

- **NCT ID:** NCT05643508
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-23
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-09-10
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643508, "A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05643508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*